We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Samaritan Pharmaceuticals Inc., a developer of innovative drugs, is pleased to announce it has purchased back the Canadian licensing rights related to HIV drug Anticort from Quest PharmaTech, Inc. (previously known as Altachem Pharma, Inc. and Steroidogenesis Inhibitors Canada, Inc.).
Genentech Inc. is laying the legal groundwork for a possible near-doubling of its work space in South San Francisco during the next decade, said a spokeswoman familiar with the new master plan that the biotechnology giant has been drafting with the help of city planners.
The U.S. Food and Drug Administration's proposed changes for the purchase of the emergency contraceptive pill known as Plan B would set back access rights for younger females of child-bearing age in the state of Hawaii.
Johnson & Johnson filed a lawsuit in Texas late last month that alleges Wyeth's widely used Effexor XR depression medicine infringes one of J&J's patents, Wyeth said.
Shares of Bristol-Myers Squibb Co. sank more than 6 percent Tuesday as a generic drug maker disclosed it has begun selling a cheaper version of the big pharmaceutical company's best-selling drug Plavix.
Less than two weeks after recalling a single lot of its Ultravist Injection X-ray contrast agent, Berlex announced July 31 the recall of all lots worldwide.
The FDA is amending the final monograph for OTC nasal decongestant drugs to add phenylephrine bitartrate (PEB), both individually and in combination drug products in an effervescent dosage form, as generally recognized as safe and effective.
The long-awaited effort to overhaul the nation's drug safety efforts faces FDA opposition as agency officials reject a recent legislative proposal to improve risk management plans as "unrealistic."